Development PipelineSGN-EGFRd2

an investigational bispecific gamma delta (γδ)-T cell engager directed to EGFR

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNEGFRd2-001: Advanced solid tumors

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

Detailed information about SGN-EGFRd2 clinical trials